ESC 365 - Non-VKA oral anticoagulation in atrial fibrillation: an overview of seminal studies.

Open Access

Non-VKA oral anticoagulation in atrial fibrillation: an overview of seminal studies.

Session: Interpreting findings with non-vitamin K antagonist (VKA) oral anticoagulants in atrial fibrillation – Collective views on data from seminal studies to present clinical practice

Topic: Atrial fibrillation (AF)

Speaker: Doctor J. Cox (Halifax, CA)

Sponsored by Bayer Pharma AG

Event: ESC Congress 2016

Congress Presentation

About the speaker

Doctor Jafna Cox

Dalhousie University, Halifax (Canada)

6 presentations

0 follower

4 more presentations in this session

From large-scale study to larger-scale practice: how do real-world findings for non-VKA oral anticoagulants stack up?

Speaker: Doctor M. Patel (Durham, US) Doctor E. Peterson (Dallas, US)

Day-to-day management of patients with atrial fibrillation on non-VKA oral anticoagulant therapy – Practical perspectives.

Speaker: Associate Professor P. Verhamme (Leuven, BE)

The management of patients with atrial fibrillation and renal impairment – Practical perspectives.

Speaker: Doctor J. Cox (Halifax, CA)

Closing remarks: interpreting findings with non-vitamin K antagonist (VKA) oral anticoagulants in atrial fibrillation – Collective views on data from seminal studies to present clinical practice.

Speaker: Professor C. Bode (Freiburg im Breisgau, DE)

Access the full session

Interpreting findings with non-vitamin K antagonist (VKA) oral anticoagulants in atrial fibrillation – Collective views on data from seminal studies to present clinical practice

Speakers: Doctor J. Cox, Doctor M. Patel, Doctor E. Peterson, Associate Professor P. Verhamme, Doctor J. Cox...

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by